The cell line is not validated yet.
BIHi005-A-97
General
Cell Line |
|
| hPSCreg name | BIHi005-A-97 |
| Cite as: | BIHi005-A-97 |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 28th April 2025 |
| User feedback | |
Provider |
|
| Generator | Berlin Institute of Health (BIH) |
External Databases |
|
| BioSamples | SAMEA118142305 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | asian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | Mutation in the LMNA gene in other family members but not in this sample frame shift mutation in the LMNA gene that leads to the early termination of translation (c. 349_350insG; p. K117fs) |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
| All cell lines of this donor's relatives |
Has brother:
|
External Databases (Donor) |
|
| BioSamples | SAMEA104012190 |
Ethics
Also have a look at the ethics information for the parental line
BIHi005-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
BIHi005-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | mRNA Miltenyi |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
Immunostaining
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
|
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Other Genotyping (Cell Line) |
Genetic Modification
| Disease/phenotype related modifications |
Synonyms
Genetic modifications
Isogenic modification
2p23.3
NC_000002.12(NM_000939.4):c.[246C>T;251G>A]
NM_000939.4(NP_000930.1):p.W84*
Heterozygous
Mutated
|
Login to share your feedback, experiences or results with the research community.